proxyvotesnow.com

Home › Companies › Trevi Therapeutics, Inc. › 2024-2025

Trevi Therapeutics, Inc. 2024-2025 Proxy Voting Records

Compiled from SEC Form N-PX filings and Trevi Therapeutics, Inc.’s Form 8-K, filed 2025-06-17 (Item 5.07 on EDGAR). Page generated 04 October 2026.

  • 7Reported items
  • 132Asset managers
  • 934Fund votes
  • 2025-06-11Meeting date

Proxy season: 2024-2025 2025-2026

Explore Trevi Therapeutics, Inc. in the interactive database Compare manager voting policies

Official 2024-2025 meeting results reported by Trevi Therapeutics, Inc.

These tallies are Trevi Therapeutics, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2025-06-17 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Trevi Therapeutics, Inc. — official shareholder meeting results, meeting held 2025-06-11
Ballot itemForAgainst AbstainWithheldBroker non-votesOutcome
Elect Director: Jennifer Good 78,827,140---- 268,1299,892,671 Majority: yes
Elect Director: Anne VanLent 62,868,529---- 16,226,7409,892,671 Majority: yes
Proposal 2: The appointment of Ernst & Young LLP as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2025 was ratified. 88,898,35756,82432,759 ---- Majority: yes
Proposal 3: The compensation of the Company's named executive officers was approved, on an advisory basis. 78,346,572722,44926,248 --9,892,671 Passed
Proposal 5: The amendment to the 2019 Plan to increase the number of shares available for issuance under the plan by 6,000,000 shares of common stock, and make certain other amendments, was approved. 78,703,357370,38021,532 --9,892,671 Passed

Source: Trevi Therapeutics, Inc., Form 8-K, filed with the SEC on 2025-06-17 — read the filing on EDGAR.

How asset managers voted at the Trevi Therapeutics, Inc. 2024-2025 meeting

Each item below shows how the 132 asset managers that disclosed a Trevi Therapeutics, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of Trevi Therapeutics, Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. APPROVAL, ON AN ADVISORY BASIS, OF THE COMPENSATION PAID TO OUR NAMED EXECUTIVE OFFICERS.

SECTION 14A SAY-ON-PAY VOTESCompany result: Passed

Combines 5 wordings of this item as funds reported it.

99.0% Passed · of votes cast

FOR 99.0%
FOR: 78,346,572AGAINST: 722,449

Trevi Therapeutics, Inc.’s own tally for this item (“Proposal 3: The compensation of the Company's named executive officers was approved, on an advisory basis.”): 78,346,572 for, 722,449 against — passed, per its Form 8-K filed 2025-06-17 (Item 5.07). Of all 99,892,915 outstanding shares: 78% for, 0.8% against (79% of the company cast a for/against vote).

The 130 asset managers below cast 99% of the shares they voted on this item FOR (70,154,317 for, 713,873 against).

FOR 99%
FOR: 70,154,317 (99.0%)AGAINST: 713,873 (1.0%)ABSTAIN: 18,119 (0.0%)
Largest asset managers voting on “APPROVAL, ON AN ADVISORY BASIS, OF THE COMPENSATION PAID TO OUR NAMED EXECUTIVE OFFICERS.” at Trevi Therapeutics, Inc., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Frazier Life Sciences Management, L.P.10,259,4090 00For
NEA Management Company, LLC9,434,6120 00For
BlackRock4,784,10623,016 00For
Point724,712,8290 00For
Rubric Capital Management LP4,325,7720 00For
Vanguard4,111,0250 00For
Vivo Capital, LLC3,487,9030 00For
VIKING GLOBAL INVESTORS LP3,227,7920 00For
Siren, L.L.C.2,461,9870 00For
MPM BioImpact LLC2,228,8860 00For
MARSHALL WACE, LLP2,196,5530 00For
Octagon Capital Advisors LP2,141,5870 00For
Woodline Partners LP1,622,0980 00For
GEODE CAPITAL MANAGEMENT, LLC1,604,1740 00For
Fidelity1,502,2340 00For
BALYASNY ASSET MANAGEMENT L.P.1,411,9630 00For
State Street1,404,933662 00For
BRAIDWELL LP1,289,6600 00For
Affinity Asset Advisors, LLC985,8640 00For
ORBIMED ADVISORS LLC893,0000 00For
Ally Bridge Group (NY) LLC740,8850 00For
Northern Trust508,0870 00For
Charles Schwab423,8460 00For
SEI395,5550 00For
SILVERARC CAPITAL MANAGEMENT, LLC368,6000 00For

Showing the 25 largest of 130 asset managers. See all 130 in the interactive database.

2. APPROVAL, ON AN ADVISORY BASIS, OF THE FREQUENCY OF FUTURE ADVISORY VOTES TO APPROVE THE COMPENSATION PAID TO OUR NAMED EXECUTIVE OFFICERS.

SECTION 14A SAY-ON-PAY VOTES

Combines 3 wordings of this item as funds reported it.

99.9% fund support · no official result

ONE YEAR 51.1%1 YEAR 46.5%

The 126 asset managers below cast 99.9% of the shares they voted on this item FOR (1,600,267 for, 848 against).

FOR: 1,600,267 (2.2%)AGAINST: 848 (0.0%)ABSTAIN: 18,119 (0.0%)ONE YEAR: 36,511,813 (51.1%)1 YEAR: 33,252,960 (46.5%)THREE YEARS: 70,297 (0.1%)3 YEARS: 6,585 (0.0%)
Largest asset managers voting on “APPROVAL, ON AN ADVISORY BASIS, OF THE FREQUENCY OF FUTURE ADVISORY VOTES TO APPROVE THE COMPENSATION PAID TO ” at Trevi Therapeutics, Inc., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Frazier Life Sciences Management, L.P.00 00One Year
NEA Management Company, LLC00 001 Year
BlackRock00 001 Year
Point7200 00One Year
Rubric Capital Management LP00 001 Year
Vanguard00 00One Year
Vivo Capital, LLC00 00One Year
VIKING GLOBAL INVESTORS LP00 00One Year
Siren, L.L.C.00 001 Year
MPM BioImpact LLC00 001 Year
MARSHALL WACE, LLP00 001 Year
Octagon Capital Advisors LP00 001 Year
Woodline Partners LP00 00One Year
GEODE CAPITAL MANAGEMENT, LLC00 00One Year
Fidelity00 00One Year
BALYASNY ASSET MANAGEMENT L.P.00 001 Year
State Street00 00One Year
BRAIDWELL LP00 00One Year
Affinity Asset Advisors, LLC00 001 Year
ORBIMED ADVISORS LLC00 001 Year
Opaleye Management Inc.795,0000 00For
Ally Bridge Group (NY) LLC740,8850 00For
Northern Trust00 001 Year
Charles Schwab00 001 Year
SEI00 001 Year

Showing the 25 largest of 126 asset managers. See all 126 in the interactive database.

3. APPROVAL OF AN AMENDMENT TO THE TREVI THERAPEUTICS, INC. 2019 STOCK INCENTIVE PLAN TO INCREASE THE NUMBER OF SHARES AVAILABLE FOR ISSUANCE UNDER THE PLAN BY 6,000,000 SHARES OF COMMON STOCK, AND MAKE CERTAIN OTHER AMENDMENTS.

COMPENSATIONCompany result: Passed

Combines 2 wordings of this item as funds reported it.

99.5% Passed · of votes cast

FOR 99.5%
FOR: 78,703,357AGAINST: 370,380

Trevi Therapeutics, Inc.’s own tally for this item (“Proposal 5: The amendment to the 2019 Plan to increase the number of shares available for issuance under the plan by 6,000,000 shares of common stock, and make certain other amendments, was approved.”): 78,703,357 for, 370,380 against — passed, per its Form 8-K filed 2025-06-17 (Item 5.07). Of all 99,892,915 outstanding shares: 79% for, 0.4% against (79% of the company cast a for/against vote).

The 40 asset managers below cast 99.5% of the shares they voted on this item FOR (19,372,941 for, 83,236 against).

FOR 99.4%
FOR: 19,372,941 (99.5%)AGAINST: 83,236 (0.4%)ABSTAIN: 18,119 (0.1%)
Largest asset managers voting on “APPROVAL OF AN AMENDMENT TO THE TREVI THERAPEUTICS, INC. 2019 STOCK INCENTIVE PLAN TO INCREASE THE NUMBER OF S” at Trevi Therapeutics, Inc., 2024-2025
Asset managerForAgainst AbstainWithheldVote
NEA Management Company, LLC9,434,6120 00For
Vanguard4,014,6670 00For
BlackRock2,890,9540 00For
Fidelity1,495,7350 00For
TIAA265,7060 00For
Charles Schwab211,9230 00For
Equitable152,4150 00For
SEI145,2680 00For
QUANTITATIVE MASTER SERIES LLC126,7790 00For
Lincoln Financial92,6590 00For
American Century076,904 00Against
Brighthouse26,8290 18,1190For
Global X43,3270 00For
BRIDGEWAY FUNDS INC42,8810 00For
Invesco41,4930 00For
AIG/SunAmerica38,0620 00For
Northern Trust35,2160 00For
MASTER INVESTMENT PORTFOLIO32,9500 00For
Dimensional30,2740 00For
Pacific Life27,9350 00For
State Street25,2120 00For
John Hancock24,7180 00For
AQR23,9600 00For
Bridge Builder Trust21,8720 00For
Voya19,8300 00For

Showing the 25 largest of 40 asset managers. See all 40 in the interactive database.

4. Election of two Class III directors to our Board of Directors, each to serve until the 2028 Annual Meeting of Stockholders: Anne VanLent

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

79% Majority: yes · of votes cast

FOR 79%WITHHELD 21%
FOR: 62,868,529WITHHELD: 16,226,740

Trevi Therapeutics, Inc.’s own tally for this item (“Elect Director: Anne VanLent”): 62,868,529 for, 16,226,740 withheld, per its Form 8-K filed 2025-06-17 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 99,892,915 outstanding shares: 63% for, 16% withheld (79% of the company cast a for/withheld vote).

The 39 asset managers below cast 100% of the shares they voted on this item FOR (6,559,311 for, 0 against).

FOR 65%ABSTAIN 35%
FOR: 6,559,311 (65.3%)ABSTAIN: 3,480,373 (34.7%)
Largest asset managers voting on “Election of two Class III directors to our Board of Directors, each to serve until the 2028 Annual Meeting of ” at Trevi Therapeutics, Inc., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard4,014,6670 00For
BlackRock525,8260 2,365,1280Abstain
Fidelity1,495,7350 00For
TIAA265,7060 00For
Charles Schwab211,9230 00For
Equitable00 152,4150Abstain
SEI00 145,2680Abstain
QUANTITATIVE MASTER SERIES LLC00 126,7790Abstain
Lincoln Financial00 92,6590Abstain
American Century00 76,9040Abstain
Brighthouse00 44,9480Abstain
Global X00 43,3270Abstain
BRIDGEWAY FUNDS INC00 42,8810Abstain
Invesco00 41,4930Abstain
AIG/SunAmerica00 38,0620Abstain
Northern Trust00 35,2160Abstain
MASTER INVESTMENT PORTFOLIO32,9500 00For
Dimensional00 30,2740Abstain
Pacific Life00 27,9350Abstain
State Street00 25,2120Abstain
John Hancock00 24,7180Abstain
AQR00 23,9600Abstain
Bridge Builder Trust00 21,8720Abstain
Voya00 19,8300Abstain
ProShares00 18,4850Abstain

Showing the 25 largest of 39 asset managers. See all 39 in the interactive database.

5. Election of two Class III directors to our Board of Directors, each to serve until the 2028 Annual Meeting of Stockholders: Jennifer Good

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

99.6% Majority: yes · of votes cast

FOR 99.6%
FOR: 78,827,140WITHHELD: 268,129

Trevi Therapeutics, Inc.’s own tally for this item (“Elect Director: Jennifer Good”): 78,827,140 for, 268,129 withheld, per its Form 8-K filed 2025-06-17 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 99,892,915 outstanding shares: 79% for, 0.3% withheld (79% of the company cast a for/withheld vote).

The 39 asset managers below cast 100% of the shares they voted on this item FOR (9,975,534 for, 0 against).

FOR 99.3%
FOR: 9,975,534 (99.4%)ABSTAIN: 64,150 (0.6%)
Largest asset managers voting on “Election of two Class III directors to our Board of Directors, each to serve until the 2028 Annual Meeting of ” at Trevi Therapeutics, Inc., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard4,014,6670 00For
BlackRock2,890,9540 00For
Fidelity1,495,7350 00For
TIAA265,7060 00For
Charles Schwab211,9230 00For
Equitable152,4150 00For
SEI145,2680 00For
QUANTITATIVE MASTER SERIES LLC126,7790 00For
Lincoln Financial92,6590 00For
American Century76,9040 00For
Brighthouse26,8290 18,1190For
Global X43,3270 00For
BRIDGEWAY FUNDS INC42,8810 00For
Invesco41,4930 00For
AIG/SunAmerica38,0620 00For
Northern Trust35,2160 00For
MASTER INVESTMENT PORTFOLIO32,9500 00For
Dimensional00 30,2740Abstain
Pacific Life27,9350 00For
State Street25,2120 00For
John Hancock24,7180 00For
AQR23,9600 00For
Bridge Builder Trust21,8720 00For
Voya19,8300 00For
ProShares18,4850 00For

Showing the 25 largest of 39 asset managers. See all 39 in the interactive database.

6. RATIFICATION OF THE APPOINTMENT OF ERNST & YOUNG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2025.

AUDIT-RELATEDMajority of the votes cast: yes

Combines 2 wordings of this item as funds reported it.

99.9% Majority: yes · of votes cast

FOR 99.9%
FOR: 88,898,357AGAINST: 56,824

Trevi Therapeutics, Inc.’s own tally for this item (“Proposal 2: The appointment of Ernst & Young LLP as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2025 was ratified.”): 88,898,357 for, 56,824 against, per its Form 8-K filed 2025-06-17 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 99,892,915 outstanding shares: 89% for, 0.1% against (89% of the company cast a for/against vote).

The 39 asset managers below cast 100% of the shares they voted on this item FOR (10,021,565 for, 0 against).

FOR 99.8%
FOR: 10,021,565 (99.8%)ABSTAIN: 18,119 (0.2%)
Largest asset managers voting on “RATIFICATION OF THE APPOINTMENT OF ERNST & YOUNG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR ” at Trevi Therapeutics, Inc., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard4,014,6670 00For
BlackRock2,890,9540 00For
Fidelity1,495,7350 00For
TIAA265,7060 00For
Charles Schwab211,9230 00For
Equitable152,4150 00For
SEI145,2680 00For
QUANTITATIVE MASTER SERIES LLC126,7790 00For
Lincoln Financial92,6590 00For
American Century76,9040 00For
Brighthouse26,8290 18,1190For
Global X43,3270 00For
BRIDGEWAY FUNDS INC42,8810 00For
Invesco41,4930 00For
AIG/SunAmerica38,0620 00For
Northern Trust35,2160 00For
MASTER INVESTMENT PORTFOLIO32,9500 00For
Dimensional30,2740 00For
Pacific Life27,9350 00For
State Street25,2120 00For
John Hancock24,7180 00For
AQR23,9600 00For
Bridge Builder Trust21,8720 00For
Voya19,8300 00For
ProShares18,4850 00For

Showing the 25 largest of 39 asset managers. See all 39 in the interactive database.

7. Advisory Vote on Say on Pay Frequency

COMPENSATION

— fund support · no official result

ONE YEAR 65%1 YEAR 35%

No shares were cast for or against this item by the managers below — every disclosed position was an abstention or was not voted.

ONE YEAR: 33,720 (65.2%)1 YEAR: 17,996 (34.8%)
Largest asset managers voting on “Advisory Vote on Say on Pay Frequency” at Trevi Therapeutics, Inc., 2024-2025
Asset managerForAgainst AbstainWithheldVote
JPMorgan00 00One Year
FORUM FUNDS II00 001 Year

Largest Trevi Therapeutics, Inc. shareholders voting in 2024-2025

Ranked by the number of Trevi Therapeutics, Inc. shares each manager voted on the most widely held ballot item of the 2024-2025 meeting, shown as a share of the 99,892,915 shares outstanding at the time of that meeting.

Top Trevi Therapeutics, Inc. shareholders by shares voted, 2024-2025
#Asset manager % of shares outstanding
1Frazier Life Sciences Management, L.P. 10.27%
2NEA Management Company, LLC 9.44%
3BlackRock 4.81%
4Point72 4.72%
5Rubric Capital Management LP 4.33%
6Vanguard 4.12%
7Vivo Capital, LLC 3.49%
8VIKING GLOBAL INVESTORS LP 3.23%
9Siren, L.L.C. 2.46%
10MPM BioImpact LLC 2.23%

Reported Trevi Therapeutics, Inc. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

Trevi Therapeutics, Inc. beneficial owners on record for the 2024-2025 proxy season
Holder % outstanding Disclosure
New Enterprise Associates 16, L.P. 15.09% 13D
James N. Topper 10.27% 13G
Frazier Life Sciences Public Fund, L.P. 8.52% 13G
FMR LLC 8.05% 13G
BlackRock 5.32% 13F
VIKING GLOBAL INVESTORS LP 5.13% 13G
Vanguard Group 3.84% 13F
Point72 2.37% 13F
Geode Capital 1.62% 13F
State Street 1.43% 13F

Percentages above are of 99,892,915 shares outstanding, as reported by Trevi Therapeutics, Inc. on its Form 10-Q dated 2025-03-31 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Trevi Therapeutics, Inc.’s 10-Q dated 2025-03-31. This page is a static snapshot rebuilt weekly on 04 October 2026; a live search always shows the current data.

At Trevi Therapeutics, Inc.'s shareholder meeting held 2025-06-11, in the 2024-2025 proxy season, 132 asset managers reported how they voted in their SEC Form N-PX filings, covering 934 separate fund positions. Their filings are grouped here into 7 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — APPROVAL, ON AN ADVISORY BASIS, OF THE COMPENSATION PAID TO OUR NAMED EXECUTIVE OFFICERS. — the proposal passed with 99.0% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Trevi Therapeutics, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2025-06-17.

Trevi Therapeutics, Inc. proxy season coverage: 2024-2025 (this page) · 2025-2026.